risedronic acid has been researched along with Hearing Loss, Sensorineural in 3 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Hearing Loss, Sensorineural: Hearing loss resulting from damage to the COCHLEA and the sensorineural elements which lie internally beyond the oval and round windows. These elements include the AUDITORY NERVE and its connections in the BRAINSTEM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Otosclerosis is a disease of abnormal bone remodeling in the otic capsule." | 1.38 | Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis. ( Halpin, C; McKenna, MJ; Merchant, SN; Quesnel, AM; Seton, M, 2012) |
| "Otosclerosis is a bony dyscrasia characterized by histopathological findings of osteoclast production." | 1.35 | Medical treatment of otosclerosis: rationale for use of bisphosphonates. ( Brookler, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brookler, K | 1 |
| Brookler, KH | 1 |
| Quesnel, AM | 1 |
| Seton, M | 1 |
| Merchant, SN | 1 |
| Halpin, C | 1 |
| McKenna, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Bisphosphonates on OI-Related Hearing Loss: A Pilot Study[NCT04152551] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for risedronic acid and Hearing Loss, Sensorineural
| Article | Year |
|---|---|
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined | 2008 |
Monaural diplacusis with tinnitus, aural fullness, hyperacusis, and sensorineural hearing loss.
Topics: Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Etidronic Acid; Hearing Loss, Sensorine | 2009 |
Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.
Topics: Adult; Aged; Audiometry, Pure-Tone; Auditory Threshold; Bone Conduction; Bone Density Conservation A | 2012 |